AZN has been the topic of a number of other research reports. Deutsche Bank lowered their price objective on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 5,700 ($74.48) and set a buy rating on the stock in a research note on Friday, July 20th. BNP Paribas set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Tuesday, September 11th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Tuesday, September 25th. Barclays set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Friday, July 27th. Finally, Jefferies Financial Group set a GBX 6,200 ($81.01) price objective on shares of AstraZeneca and gave the company a neutral rating in a research note on Thursday, August 16th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Hold and an average target price of GBX 5,831.89 ($76.20).
LON AZN opened at GBX 6,172 ($80.65) on Tuesday. AstraZeneca has a 12 month low of GBX 4,260 ($55.66) and a 12 month high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Leveraged Buyout (LBO)
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.